Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

Oncology has entered a new era with the approval of anti-cancer drugs that harness a patient’s immune system to fight back against cancer. NOXXON’s tumor microenvironment approach to disrupting cancer’s ability to escape the immune system’s attack is unique in the biopharmaceutical industry because it directly blocks tumor’s ability to exploit the molecular signposts in the body used by cells on the move. The therapeutic goal is to remove the barriers or “detour” signs cancers build to keep the immune system away.

NOXXON is intensely focused on advancing its innovative therapeutic candidates through clinical development to demonstrate their potential for improving outcomes for cancer patients. Our compounds are designed to enhance the efficacy of both novel immuno-oncology approaches, such as immune checkpoint inhibitors, and current standards of care, such as chemotherapy and radiotherapy. Our proprietary product candidates, discovered and developed by NOXXON, based on our unique (Spiegelmer*) drug discovery platform, are centered on targeting the tumor microenvironment and disrupting the signaling cancer cells use to deflect immune system detection and attack.

Our lead candidate, NOX-A12, is under development as a combination therapy for multiple cancer indications where its impact on the tumor microenvironment is intended to significantly enhance the effectiveness of anti-cancer treatments without adding significant side effects for patients. NOX-A12 is currently in a Phase 1/2 trial in metastatic pancreatic and colorectal cancer patients who are not expected to respond to checkpoint inhibition alone. NOX-A12 has also completed two Phase 2a trials, one in chronic lymphocytic leukemia and the other in in multiple myeloma. Read more here.

Our second clinical-stage oncology candidate, NOX-E36, is able to target multiple tumor microenvironment chemokines that appear to be relevant to tumor evasion of the immune system. NOX-E36 has completed exploratory clinical studies in additional indications, establishing its activity on the biological targets and its safety profile, but we are now focused in its application in oncology. Read more here.

Pipline NOXXON

1. Feig, C. et al. PNAS 110.50 (2013): 20212-20217; Fearon, D. Cancer Immunol Research 2.187 (2014): 187-193; Poznansky, M., Nature America 6:543 (2000): 543-548
2. Rocarro et al. Cell reports 9 (2014): 118-128; Marasca, R. & Maffei, R., Blood 123 (2014): 952-953
3. Liu, S. et al. Neuro-Oncology 16.1 (2013): 1-8; Castro, B. & Aghi, M. Neuro-Oncology 16.1 (2014): 4-6
4. Nywening Lancet Oncol 2016
5. Steurer, M. et al. ASH 2014 642 for CLL &  Ludwig, H. 2017 Leukemia for MM